Procept Biorobotics

Procept Biorobotics EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Procept Biorobotics (PRCT) as of Oct 30, 2026 is -20.44 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -18.09 % — a change of 12.99% (lower).

EBIT/Assets

-20.44 %

YoY

12.99%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Procept Biorobotics is 2025 -20.44 % . Operating Income to Assets Ratio (EBIT/Assets) of Procept Biorobotics was 2024 -18.09 % . It decreases by 12.99% lower compared to the previous year.

The Procept Biorobotics EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-70.25 USD
Jan 1, 2020
-38.06 USD
Jan 1, 2021
-16.07 USD
Jan 1, 2022
-27.31 USD
Jan 1, 2023
-26.97 USD
Jan 1, 2024
-18.09 USD
Jan 1, 2025
-20.44 USD
The Procept Biorobotics EBIT/Assets history
YEAREBIT/AssetsYoY
-20.44 %+12.99%
-18.09 %-32.93%
-26.97 %-1.22%
-27.31 %+69.91%
-16.07 %-57.77%
-38.06 %-45.82%
-70.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

Operating Income to Assets Ratio (EBIT/Assets) of Procept Biorobotics is -20.44 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Procept Biorobotics changed from -18.09 % to -20.44 %, representing a 12.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Procept Biorobotics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Procept Biorobotics

All Key Metrics — Procept Biorobotics